Problematic Pharmaceutical Opioid Use Common in Noncancer Pain
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 15, 2024 -- For individuals with chronic noncancer pain (CNCP) treated with opioid analgesics, problematic pharmaceutical opioid use (POU) is common, according to a study published online Aug. 7 in Addiction.
Kyla H. Thomas, Ph.D., M.B.B.S., from the University of Bristol in the United Kingdom, and colleagues conducted a comprehensive systematic literature review and meta-analysis to examine the prevalence of POU in CNCP patients (aged 12 years and older) treated with opioid analgesics. POU was defined as dependence and opioid use disorder (D&OUD), signs and symptoms of D&OUD (S&S), aberrant behavior (AB), and at risk for D&OUD. Data were included from 148 studies with more than 4.3 million participants; 1 percent of studies had a high risk for bias.
The researchers found that the pooled prevalence was 9.3 percent (I2, 99.9 percent), 29.6 percent (I2, 99.3 percent), and 22 percent (I2, 99.8 percent) for D&OUD, S&S, and AB, respectively, while prevalence of those at risk for D&OUD was 12.4 percent (I2, 99.6 percent). Study setting, study design, and diagnostic tool affected prevalence. The findings should be interpreted with caution due to high heterogeneity, according to the researchers.
"Clinicians and policymakers need a more accurate estimate of the prevalence of problematic opioid use in pain patients so that they can gauge the true extent of the problem, change prescribing guidance if necessary, and develop and implement effective interventions to manage the problem," Thomas said in a statement. "Knowing the size of the problem is a necessary step to managing it."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-16 03:15
Read more
- Men Aged >16 to
- Liquor, Wine, Beer: Which Comes With the Worst Lifestyle?
- Gabapentinoid Use Tied to Higher Risk for Hip Fractures
- Women, Men on Kidney Dialysis Face Different Heart Risks
- Merus Receives FDA Extension of PDUFA for Zenocutuzumab
- Medication Abortion Before Confirmed Intrauterine Pregnancy Noninferior
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions